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Abstract
Introduction: Pokemon is an oncogenic transcription factor involved in cell growth, differentiation and
oncogenesis, but little is known about its role in human breast cancer. In this study, we aimed to reveal the role of
Pokemon in breast cancer progression and patient survival and to understand its underlying mechanisms.
Methods: Tissue microarray analysis of breast cancer tissues from patients with complete clinicopathological data
and more than 20 years of follow-up were used to evaluate Pokemon expression and its correlation with the
progression and prognosis of the disease. DNA microarray analysis of MCF-7 cells that overexpress Pokemon was
used to identify Pokemon target genes. Chromatin immunoprecipitation (ChIP) and site-directed mutagenesis were
utilized to determine how Pokemon regulates survivin expression, a target gene.
Results: Pokemon was found to be overexpressed in 158 (86.8%) of 182 breast cancer tissues, and its expression
was correlated with tumor size (P = 0.0148) and lymph node metastasis (P = 0.0014). Pokemon expression led to
worse overall (n = 175, P = 0.01) and disease-related (n = 79, P = 0.0134) patient survival. DNA microarray analyses
revealed that in MCF-7 breast cancer cells, Pokemon regulates the expression of at least 121 genes involved in
several signaling and metabolic pathways, including anti-apoptotic survivin. In clinical specimens, Pokemon and
survivin expression were highly correlated (n = 49, r = 0.6799, P < 0.0001). ChIP and site-directed mutagenesis
indicated that Pokemon induces survivin expression by binding to the GT boxes in its promoter.
Conclusions: Pokemon promotes breast cancer progression by upregulating survivin expression and thus may be a
potential target for the treatment of this malignancy.
Introduction
Pokemon, also referred to as a factor that binds to indu-
cer of shot transcript 1 (FBI) or leukemia/lymphoma-
related factor (LRF), is the product of the ZBTB7 gene
[1]. Pokemon is a pro-oncogenic protein overexpressed
in lung cancer, diffuse large B-cell lymphomas
(DLBCLs), non-Hodgkin’s lymphoma (NHL), liver can-
cer, follicular lymphomas and breast cancer [1-4]. In
animals, Pokemon was found to induce cell transforma-
tion by repressing the tumor suppressor ARF/p53 path-
way [1]. In addition, Pokemon is implicated in
transactivation of the human immunodeficiency virus
(HIV)-1 Tat gene, adipogenesis, osteoclastogenesis and
fatty acid synthesis [5-8]. However, the expression and
role of Pokemon in human breast cancer remains
unclear.
Pokemon functions as a transcription regulator with
active roles in cell growth, differentiation and oncogen-
esis [2,9,10]. Pokemon interferes with GC box recogni-
tion by Sp1 via interacting with the zinc finger DNA
binding domain, resulting in the repression of ADH5/
FDH transcription [11]. Pokemon also affects the tran-
scription of nuclear factor (NF)-B-responsive genes by
associating with the p65 subunit and inducing its
nuclear import and stabilization [12]. The target genes
of Pokemon include extracellular matrix collagen types
I, II, IX, X and XI; aggrecan; fibronectin; elastin; carti-
lage oligomeric matrix protein (COMP); alcohol dehy-
drogenase ADH5/FDH, ARF and Rb tumor suppressors;
and c-fos and c-myc oncoproteins [9,11-15]. In this
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study, we found that in breast cancer cells, Pokemon sti-
mulates survivin expression by binding to its promoter.
Survivin, a member of the inhibitor of apoptosis pro-
teins (IAP) [16], plays an important role in cell apopto-
sis and mitotic regulation. Survivin is expressed in fetal
and cancer cells, but not in normal adult cells. Survivin
is highly expressed in breast, colorectal, lung, gastric
and bladder cancers, as well as in melanoma, hepatocel-
lular carcinoma and malignant lymphoma, and its
expression in these cancers is associated with poor clini-
cal prognosis [17-25]. Much effort has been made to
understand the regulatory mechanism of survivin
expression. Various studies have shown that survivin
expression is regulated by multiple oncogenes, tumor
suppressors and growth factors, such as p53, Sp1, Krüp-
pel-like factor 5 (KLF5) and epidermal growth factor
receptor (EGFR) [26-30]. In the present study, we found
that survivin expression is correlated with Pokemon
expression in human breast cancer cells and demon-
strated that Pokemon induces its expression by binding
to the GC boxes in its promoter.
Materials and methods
Tissue microarray and clinical data
Microarrays of human breast carcinomas were provided
by the Yale Cancer Center Critical Technologies group.
Two microarrays were used in this study: Yale Tissue
Microarray (YTMA) -23, containing 246 breast cancer
cases with complete clinical records and more than 30
years of follow-up (Additional file 1), and YTMA-89,
consisting of 54 recurrent breast cancer cases. Paraffin-
embedded, formalin-fixed specimens of breast carci-
noma tissue were identified from the archives of the
Yale University Department of Pathology as available
from 1961 to 1983. Complete treatment information
was unavailable for the entire cohort of 246 primary
breast cancer cases, but most patients were treated with
postsurgical local radiation. None of the node-negative
patients were given adjuvant systemic therapy. Among
the node-positive patients, approximately 15% were
given chemotherapy primarily consisting of adriamycin,
cytoxan and 5-fluorouracil, and some were given tamox-
ifen (post-1978) [31,32]. Another two adjacent arrays
composed of 50 breast cancers with matching normal
adjacent tissues were obtained from Cybrdi, Inc. (CC08-
1-07; Cybrdi, Inc., Rockville, MD, USA). Ethical approval
for this study was obtained from the human research
ethical advisory committee of Tsinghua University.
Cell culture
The human breast cancer cells MCF-7 and MDA-MB-
231 (American Type Culture Collection, Manassas, VA,
USA) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heated fetal
bovine serum (FBS), 2 mM glutamine, 100 U/ml penicil-
lin and 100 μg/ml streptomycin at 37°C and 5% CO2.
Immunohistochemistry
After dewaxing and hydration, tissue microarray slides
were immersed into preheated citric acid buffer (pH 6.5)
at 90°C to 95°C for 20 minutes with microwaving. After
being blocked with 5% horse serum for 30 minutes,
slides were incubated with anti-Pokemon or anti-survi-
vin antibodies (1:50; Abcam, Cambridge, MA, USA) at
4°C in a humid box overnight. Thereafter slides were
washed three times and then incubated with horseradish
peroxidase-conjugated secondary antibody (1:800; Pierce
Biotechnology, Rockford, IL, USA) at room temperature
for 1 hour. Enhanced 3,3’-diaminobenzidine staining
buffer (Pierce Biotechnology) was used to visualize sig-
nals. Staining intensity was evaluated blindly by at least
one researcher and one pathologist and was scored from
0 to 3, representing negative and low, intermediate and
high staining, respectively.
Plasmid construction
Pokemon-expressing plasmid was generated by inserting
the encoding region into pcDNA3.1 expression vector
(Invitrogen, Carlsbad, CA, USA) at the site of the Hin-
dIII restriction enzyme. Pokemon primer pairs were 5’-
CTT AAG CTT GCC ACC ATG GCC GGC GGC
GTG G-3’ and 5’-GTC AAG CTT TTA GGC GAG
TCC GGC TGT GAA GTT AC-3’. Survivin promoter
was subcloned into pGL4.10 basic plasmid (Promega,
Madison, WI, USA) at the BamHI and EcoRV restriction
enzyme sites to drive luciferase expression. The amplifi-
cation primer pairs were 5’-GTC AGA TCT AGT GAA
AAG GAG TTG TTC CTT TCC TCC CTC-3’ and 5’-
GTC AAG CTT GCC GCC GCC GCC ACC TC-3’ for
a 2,082-bp fragment, 5’-GTC AAG CTT GCC GCC
GCC GCC GCC ACC TC-3’ and 5’-GTC AGA TCT
AAA GAC AGT GGA GGC ACC AGG C-3’ for a
1,054-bp fragment, and 5’-GTC AAG CTT GCC GCC
GCC GCC ACC TC-3’ and 5’-GTC AGA TCT TTG
GGA TTA CAG GCA TGC ACC AC-3’ for a 441-bp
fragment.
Site-directed mutagenesis
Mutants (pLuc-95 m and pLuc-231 m) of survivin pro-
moter were generated using an in vitro site-directed
mutagenesis system (Promega). The GGGTG sequence
in the binding site of Pokemon was replaced by
AAAAA and confirmed by sequencing.
cDNA microarray analysis
Human cDNA microarrays covering 22 kb cDNA spots
(CapitalBio, Beijing, China) were used. In brief, total
RNA was extracted from MCF-7 cells with ectopic
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Pokemon expression and vector control using the TRIzol
reagent (Invitrogen), and fluorescence-labeled cDNA
probes were made for hybridization using 30 μg of total
RNA with an oligo(dT)18 primer and SuperScript II
Reverse Transcriptase (Gibco BRL, Carlsbad, CA, USA).
Hybridized slides were scanned using a LuxScan 10K-A
confocal laser microscopy scanner, and signal intensities
for each spot were calculated by subtracting local back-
ground using LuxScan 3.0 software (CapitalBio). Three
independent replicates were conducted, and the spot
with ≥2.0-fold increase or decrease was considered a sig-
nificant change. Gene expression signaling pathways
were analyzed with MAS2.0 software (CapitalBio) [GEO:
GSE27442].
Pokemon silencing and Western blot analysis
Pokemon expression in MDA-MD-231 breast cancer cells
was knocked down using chemically synthesized small
interfering RNA (siRNA) siRNA#1 (targeting 426 to 444
bp, sense 5’-GCU GGA CCU UGU AGA UCA Att-3’, and
antisense 5’-UUG AUC UAC AAG GUC CAG Ctt-3’),
siRNA#2 (targeting 476 to 494 bp, sense 5’-AGU ACC
UCG AGU UCU UCC Att-3’, and antisense 5’-UGG AAG
AAC UCG AGG UAC Utt-3’) [13] and siRNA#3 (targeting
624 to 642 bp, sense 5’-GGA GUA CCU CGA GUU CUU
Ctt-3’, and antisense 5’-GAA GAA CUC GAG GUA CUC
Ctt-3’). The siRNA were introduced as described pre-
viously [33], and protein knockdown was examined using
Western blot analysis [34]. Soluble proteins (30 μg) were
probed with anti-Pokemon (1:500), anti-survivin, anti-
p14ARF and anti-Bcl-2 antibodies (1:500) (Abcam). Load-
ing variations were normalized against b-actin, which was
identified by anti-b-actin monoclonal antibody (Sigma, St.
Louis, MO, USA).
Transient transfection and luciferase activity assay
Transient gene delivery was carried out to assess the
effect of Pokemon on survivin promoter activity in
MDA-MB-231 and MCF-7 cells as described previously
[35,36]. Briefly, 1 × 105 cells were mixed with survivin
promoter constructs and Pokemon expression vector or
Pokemon siRNA#1. At 48 hours after transfection, cell
extracts were prepared with 1 × lysis buffer, and a 10-μl
aliquot of the supernatant was mixed with 50 μl of luci-
ferase assay reagent (Promega) and analyzed with a
Microplate Luminometer (Beckman Coulter, Fullerton,
CA, USA). Luciferase activity was normalized by using a
Renilla luciferase internal control.
Chromatin immunoprecipitation assay
MCF-7 and MDA-MB-231 cells were fixed by the addi-
tion of 1% formaldehyde to the medium for 10 minutes.
Formaldehyde was quenched by the addition of 1 × gly-
cine for 5 minutes at room temperature. A chromatin
immunoprecipitation (ChIP) assay was performed as
described previously [37] with 3 μl of immunoprecipi-
tated DNA and primers (forward 5’-GTC AAG CTT
GCC GCC GCC GCC ACC TC-3’ and reverse 5’-GTC
AGA TCT TTG GGA TTA CAG GCA TGC ACC AC-
3’) located at -441 to -418 bp and -17 to +1 bp of the
survivin promoter.
Statistical analysis
Spearman’s rank-correlation coefficients were used to
assess the relationship between Pokemon and survivin
expression, the Wilcoxon rank-sum test or the Kruskal-
Wallis test were utilized with categorical variables and
Kaplan-Meier survival curves were produced to examine
the relationship between Pokemon expression and mor-
tality. Results were considered statistically significant at
P < 0.05.
Results
Overexpression of Pokemon in breast cancer is positively
correlated with disease progression
The YTMA-23 tissue microarray, provided by the Yale
Cancer Center Critical Technology Group, was evalu-
ated for Pokemon expression. This array consists of 246
breast cancer cases and normal controls, among which
182 malignant tissues were histologically interpretable.
The results showed that Pokemon was undetectable in
normal breast lobules, but overexpressed in 158 (86.8%)
of 182 cancerous tissues. The level of Pokemon expres-
sion was assessed according to the intensity of immu-
nostaining and assigned the score of 0 to 3 (negative to
most intensive) (Figure 1A). This YTMA-23 microarray
came with complete clinical records and follow-up, and
therefore the correlation between Pokemon expression
and clinical pathological parameters was analyzed. As
summarized in Table 1, Pokemon expression correlated
positively with tumor size (P = 0.0148) and lymph node
metastasis (P = 0.0014), but not with patient age, tumor
type and nuclear grade. Pokemon was also found to be
overexpressed in 28 (80%) of 35 interpretable recurrent
breast tumors in another YTMA-89 microarray.
Tumor size and lymph node metastasis are well-
known prognostic factors for breast cancer, and there-
fore the effect of Pokemon expression on patient survival
was further analyzed using Kaplan-Meier plots. As
shown in Figure 1B, Pokemon expression was negatively
correlated with overall survival (n = 175, P = 0.01) and
in particular disease-related survival (n = 79, P =
0.0134) of breast cancer patients, indicating that Poke-
mon is a negative prognostic indicator.
The estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor receptor 2
(HER2) genes are well-established biomarkers and thera-
peutic targets for breast cancer. The correlation of
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Pokemon expression with these three molecular markers
was assessed using Kruskal-Wallis tests, and the results
showed that Pokemon expression did not correlate with
ER, PR or HER2 alone or with any combination of the
three genes.
Survivin is a downstream target of Pokemon
The positive correlation of Pokemon expression with
disease progression suggests that Pokemon may
promote cancer development. To determine the under-
lying mechanisms, we attempted to identify genes
regulated by Pokemon in MCF-7 breast cancer cells. A
total of six MCF-7 cell clones with stable Pokemon
overexpression were isolated (Additional file 2), and
three of them were subjected to cDNA microarray ana-
lysis. Figure 2 shows representative data of microarray
analysis, in which a total of 121 genes were found to
have more than a twofold increased or decreased
Figure 1 Pokemon expression in breast cancer tissues and its relationship with patient survival. (A) Immunohistochemistry indicating
Pokemon expression in normal and malignant breast tissues. Results were scored by a researcher blinded to the samples and by a pathologist.
The images show Pokemon expression in (a) normal breast lobules and in breast cancers scored as (b) 1, (c) 2 and (d) 3, respectively. (B) Kaplan-
Meier plots of (i) overall survival (n = 175, P = 0.01) and (ii) disease-related survival (n = 79, P = 0.0134). Data are from the Yale Tissue Microarray
(YTMA)-23 microarray containing 175 breast cancer cases with clinical data and more than 30 years of follow-up. In disease-related survival plots,
disease-free survival or patients who died as a result of breast cancer are included.
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expression in Pokemon-overexpressing cells compared
to the vector control. On the basis of the Kyoto Ency-
clopedia of Genes and Genomes and the Gene Ontol-
ogy databases, these genes are classified into seven
signaling and/or metabolic pathways (Figure 2C).
Notably, these Pokemon target genes are mainly
involved in apoptosis, cell cycle, differentiation and
biosynthesis, suggesting the importance of Pokemon in
cell growth, proliferation and carcinogenesis.
Interestingly, BIRC5 (survivin), a negative prognostic fac-
tor for breast cancer [38], was found to be one of the
downstream targets of Pokemon. Therefore, transfection
experiments were performed to determine the role of
Pokemon in inducing the expression of survivin. MCF-7
cells were transfected with Pokemon expression vector to
increase the level of Pokemon, while MDA-MD-231 cells
were transfected with Pokemon siRNA to knock down its
expression. As shown in Figure 2D(I), three different
siRNA targeting 426 to 444 bp, 476 to 494 bp and 624 to
642 bp of Pokemon mRNA successfully knocked down its
expression and in turn led to a decrease of survivin, prov-
ing the cDNA microarray data. A time-course study
showed that significant silencing of Pokemon by siRNA
was observed at 48 hours after transfection. Interestingly,
Pokemon silencing in MDA-MD-231 led to upregulation of
p14ARF, but had no effect on Bcl-2 expression. In addition,
transient expression of Pokemon in MCF-7 cells induced
survivin upregulation in a parallel manner to Pokemon
levels (Figure 2D(II)), supporting the cDNA microarray
data from stable clones. Taken together, these results sug-
gest that Pokemon indeed induces survivin expression.
Survivin and Pokemon expression is highly correlated in
human breast cancer tissues
To confirm that the induction of survivin by Pokemon
indeed occurs in breast cancer, adjacent tissue microar-
rays containing 50 breast cancer tissue samples and
matching adjacent normal breast tissue samples were
subjected to immunohistological analysis of Pokemon
and survivin expression. As shown in Figure 3, the levels
Table 1 Correlation of Pokemon expression with clinicopathological parametersa
Pokemon (n = 182)
Variables 3 2 1 0 P value
Subtotal, n (%) 72 (39.6) 69 (37.9) 17 (9.3) 24 (13.2)
Age, yr (%) 0.2451
>50 58 (40.8) 55 (38.7) 13 (9.2) 16 (11.3)
≤50 13 (33.3) 14 (35.9) 4 (10.3) 8 (20.5)
Tumor types, n (%) 0.8733
Colloid 3 (37.5) 3 (37.5) 1 (12.5) 1 (12.5)
Ductal 35 (47.9) 26 (35.6) 5 (6.8) 7 (9.6)
Lobular 14 (53.8) 8 (30.8) 3 (11.5) 1 (3.8)
Tumor size, cm3 (%) 0.0148
>2 47 (42.7) 46 (41.8) 9 (8.2) 8 (7.3)
≤2 23 (33.8) 22 (32.3) 8 (11.8) 15 (22.1)
Node metastasis, n (%) 0.0014
Positive 49 (44.1) 38 (34.2) 8 (7.2) 16 (14.4)
Negative 22 (31.9) 30 (43.5) 9 (13.0) 8 (11.6)
Nuclear grade, n (%) 0.057
1 5 (23.8) 9 (42.6) 2 (9.5) 5 (23.8)
2 40 (40.4) 38 (38.4) 12 (12.1) 9 (9.1)
3 25 (45.5) 20 (38.4) 3 (12.1) 7 (9.1)
ER, n (%) 0.429
Positive 38 (37.6) 39 (38.6) 11 (10.9) 13 (12.9)
Negative 34 (42.0) 30 (37.0) 6 (7.4) 11 (13.6)
PR, n (%) 0.3444
Positive 41 (40.2) 34 (33.3) 14 (13.7) 13 (12.8)
Negative 31 (38.8) 35 (43.8) 3 (3.7) 11 (14.7)
HER2, n (%) 0.2309
Positive 31 (38.7) 28 (35.0) 7 (8.8) 14 (17.5)
Negative 41 (38.3) 41 (38.3) 11 (10.3) 14 (13.1)
aData are from the Yale Tissue Microarray-23, in which 182 breast cancer cases were histologically interpretable and analyzed for the correlation of Pokemon
expression with clinicopathological parameters. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
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of survivin and Pokemon expression were found to be
highly correlated (r = 0.6799, P < 0.0001). In normal
breast tissues, the expression levels of both Pokemon
and survivin were low (data not shown).
Pokemon regulates survivin expression via DNA sequence-
specific binding to its promoter
We further explored the mechanism by which Pokemon
regulates the expression of survivin. The promoter
region of survivin, containing 2,080 bp upstream of the
transcription start site, was cloned and used to drive the
expression of luciferase reporter in MCF-7 and MDA-
MB-231 breast cancer cells. Progressive deletions of the
5’ end of the survivin promoter revealed that the -441-
bp fragment possesses full promoter activity (Figure
4A). Promoter motif analyses recognized two GT boxes
(GGGTG), located at -231 to -227 bp and -95 to -91 bp,
which are potential binding sites of Pokemon. Therefore,
Figure 2 Target genes of Pokemon in MCF-7 cells. cDNA microarray analysis was performed as described in Materials and methods. Data
from three independent replicates were combined, and any spot with at least a 2.0-fold increase or decrease compared to vector control was
considered a significant change. Signaling pathways were classified by using Molecule Annotation System (MAS) 2.0 software (CapitalBio, Beijing,
China ). (A) Ectopic expression of Pokemon in MCF-7 breast cancer cells detected by Western blot analysis. (B) Scatterplots showing differential
expression profile of Pokemon target genes in MCF-7 cells. (C) Pathway classification of Pokemon target genes in MCF-7 cells. (D) Survivin
expression regulated by Pokemon. MDA-MB-231 cells treated with siRNA for 48 hours were harvested for Western blot analysis with the
indicated antibodies (I). Cells transiently transfected with either Pokemon expression vector (MCF-7 cells) or siRNA (MDA-MB-231 cells) were used
for time-dependent expression by Western blot analysis as described in Materials and methods (II).
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this promoter fragment was used to investigate the reg-
ulatory role of Pokemon on its activity. As shown in
Figure 4B, cotransfection of PCDNA3.1(+)/Pokemon
greatly increased the activity of -pluc-441 in both MCF-
7 and MDA-MB-231 cells, while the delivery of Poke-
mon siRNA significantly reduced its basal activity, sug-
gesting Pokemon as a positive regulator of survivin
promoter. Furthermore, replacing GGGTG with
AAAAA in these two GT boxes of pluc-441 (luciferase
plasmid at -441 bp) abrogated the promoter’s respon-
siveness to Pokemon in both MCF-7 and MDA-MB-231
cells (Figure 4B), and interaction between Pokemon and
survivin promoter was further confirmed by ChIP assay.
As shown in Figure 4C, survivin promoter fragment was
Figure 3 Correlation of survivin and Pokemon expression in breast cancer tissue. Pokemon and survivin expression in breast tissues was
examined by immunohistochemistry as described in Materials and methods. (A) Images show Pokemon and survivin expression in two adjacent
sections, which are histologically similar but not the same. Red boxed regions are amplified in lower panels. (B) Summary of Pokemon and
survivin expression data. Spearman’s rank-correlation coefficients were used to test the relationship between Pokemon and survivin expression.
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amplified by polymerase chain reaction assay from chro-
matin precipitated by an anti-Pokemon antibody, but
not by nonspecific immunoglobulin G. These data sug-
gest that Pokemon upregulates survivin expression
through direct binding to the GT boxes in its promoter.
Discussion
Pokemon is an oncogenic transcription factor. Embryo-
nic fibroblasts (MEF) from Pokemon-null mice are resis-
tant to cellular or viral oncogene-induced carcinogenic






























Figure 4 Pokemon stimulates survivin expression by direct binding to its promoter. (A) Schematic representation of survivin promoter-
luciferase reporter plasmids, including wild-type survivin promoter and 5’ progressive deletions, as well as site-directed mutants at Pokemon
binding sites, pLuc-95 m (at -95 bp) and pLuc-231 m (at -231 bp). Refer to Materials and methods for the plasmid construction. Survivin
promoter activity was analyzed in MCF-7 cells by luciferase assay. (B) Regulation of survivin promoter activity by Pokemon in MCF-7 and MDA-
MB-231 breast cancer cells. Wild-type and mutant promoter (pLuc-441) was cotransfected with Pokemon gene or Pokemon small interfering RNA
siRNA#1, and luciferase activity was measured with b-galactosidase as an internal control. Data represent the mean of three independent
experiments ± SD. Statistical significance was tested using Student’s t-tests with *P < 0.05 and **P < 0.01. (C) Chromatin immunoprecipitation
assay indicating that Pokemon bound to survivin promoter in MCF-7 and MDA-MB-231 breast cancer cells. Rabbit immunoglobulin G was used
as a negative control. Refer to Materials and methods for details.
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of Pokemon makes the MEF cells susceptible to onco-
genic transformation. These findings suggest an impor-
tant role of Pokemon in carcinogenesis [10]. In this
study, we have shown that Pokemon was overexpressed
in primary and recurrent breast cancer tissues and upre-
gulated the expression of anti-apoptotic survivin, leading
to disease progression and poor survival.
Using tissue microarray technology, we have shown that
Pokemon was overexpressed in 86.8% of breast cancer tis-
sue, but not in normal beast tissue, indicating its tumor-
specific expression. More importantly, Pokemon expres-
sion correlated positively with tumor size and lymph node
metastasis, both of which are indicators of unfavorable
clinical outcome. Indeed, the level of Pokemon expression
was negatively correlated with survival rate. These findings
indicate that Pokemon may be a novel prognostic marker
for breast cancer and a potential therapeutic target. We
therefore attempted to elucidate the underlying mechan-
ism of its tumor-promoting function.
Previous studies have shown that Pokemon functions
as an oncoprotein by inhibiting the ARF/p53 pathway
[10]. Using cDNA microarray analyses, we have shown
that in breast cancer cells, Pokemon regulates the
expression of at least 121 genes, some of which are
involved in important cellular signaling/metabolic path-
ways. Survivin, an antiapoptotic protein and a negative
prognostic indicator of breast cancer [38,39], is one of
those genes whose expression was induced by Pokemon.
Our study on breast cancer tissues from 50 patients
(Figure 3) showed that the expression levels of survivin
and Pokemon were highly correlated (P < 0.0001, r =
0.6799), suggesting that Pokemon serves as an upstream
inducer of survivin in breast cancers.
Survivin is widely implicated in cell carcinogenesis,
tumor progression and resistance to radiation therapy
and chemotherapy [30,40]. Previous studies showed that
p53 is a suppressor of survivin expression and that loss
of p53 function would lead to the induction of survivin,
resulting in cancer growth and resistance to chemother-
apeutic agents [28,41]. Pokemon has been shown to
repress the expression of p53 [10,42]. Therefore, Poke-
mon may induce the expression of survivin indirectly by
suppressing p53. However, in this study, we have
demonstrated that Pokemon can directly induce the
expression of survivin by binding to the GC boxes in its
promoter. This finding reveals a new signaling pathway
of Pokemon-mediated oncogenesis and advances under-
standing of survivin regulatory mechanisms (Figure 5).
In summary, we have found that Pokemon is overex-
pressed specifically in breast cancer tissue, but not in
normal breast tissue. Its oncogenic function may be
partly due to its ability to directly induce the expression
of survivin, an important cancer-promoting gene. The
correlation of Pokemon expression with tumor size,
lymph node metastasis and poor patient survival sug-
gests its potential role as a prognostic marker and thera-
peutic target for the treatment of this disease.
Conclusions
Pokemon was overexpressed in primary and recurrent
breast cancer tissue and was correlated with tumor size,
lymph node metastasis and poor patient survival, mak-
ing it a potential target for the treatment of this malig-
nancy. Pokemon might prompt breast cancer
progression through upregulating the expression of sur-
vivin, an important cancer-promoting gene.
Additional material
Additional file 1: Descriptive statistics of tissue microarray. Yale
Tissue Microarray (YTMA)-23 contained 246 breast cancer cases with
clinical records. The descriptive statistical data are summarized below.
Additional file 2: MCF-7 cell clones with stable overexpression of
Pokemon. MCF-7 cells were transfected with pcDNA3.1/Pokemon or the
empty vector, and the transfected cells maintained with neomycin were
subjected to Western blot analysis for the detection of Pokemon
expression.
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ChIP: chromatin immunoprecipitation assay; EGFR: epidermal growth factor
receptor; FBI: factor that binds to inducer of shot transcripts 1; HER2: human
epidermal growth factor receptor 2; IAP: inhibitor of apoptosis protein; KLF5:
Krüppel-like factor 5; LRF: leukemia/lymphoma-related factor; PMSF:
phenylmethanesulfonyl fluoride.
Figure 5 Hypothetic pathways by which Pokemon regulates
survivin expression. p53 suppresses survivin expression and
induces cell apoptosis or senescence [28,29]. Pokemon activates
survivin signaling by suppressing the ARF/p53 pathway [1]. The
present study shows that Pokemon also enhances survivin
expression via direct binding to its promoter, promoting breast
oncogenesis.
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